Menu Search
Investment Trusts

The Biotech Growth Trust PLC

BIOG:LSE

The Biotech Growth Trust PLC

Actions
  • Price (GBX)891.42
  • Today's Change-30.58 / -3.32%
  • Shares traded13.99k
  • 1 Year change-44.29%
  • Beta0.8128
Data delayed at least 20 minutes, as of Jan 27 2022 08:09 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Total returns on £1000

1Y
Fund/benchmarkChange
PriceThe Biotech Growth Trust PLC (Ordinary Share)-45.13%
NAVThe Biotech Growth Trust PLC (Ordinary Share)-41.72%
Morningstar's BenchmarkNASDAQ Biotechnology TR GBP-21.43%
--

Key statistics

The Biotech Growth Trust PLC (BIOG:LSE) set a new 52-week low during Monday's trading session when it reached 875.56. Over this period, the share price is down -43.08%.
52-week range
Today
875.56Jan 24 20221,750.00Feb 10 2021
Markit short selling activity
Low
Med
High
Shares outstanding41.16m
Market cap365.49m GBP
Total assets424.33m GBP
Total expense ratio1.09%
High913.00
Low888.00
Previous close922.00
Average volume114.83k
YTD Change-24.96%
Beta0.8128
Diluted NAV (est)959.78
Diluted NAV (last pub)943.07
Premium/Discount-3.94%
Net Gearing+8.63%
Data delayed at least 20 minutes, as of Jan 27 2022 08:09 GMT.
More ▼

Annual Reports

Board of Directors

1/7

Andrew Joy, Independent Non-Executive Chairman

2/7

Geoff Hsu, Non-Executive Director

3/7

Steve Bates, Independent Non-Executive Director

4/7

Professor Dame Kay Davies CBE, Independent Non-Executive Director

5/7

Lord Willetts, Independent Non-Executive Director

6/7

Julia Le Blan, Independent Non-Executive Director

7/7

Dr Nicola Shepherd, Independent Non-Executive Director

Further Information

Contact

The Biotech Growth Trust PLC:
25 Southampton Buildings
London
WC2A 1AL

T: 0203 008 4910
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.